Cholinergic Changes in the APP23 Transgenic Mouse Model of Cerebral Amyloidosis

Alzheimer's Disease (AD) is a neurodegenerative disorder that is characterized by extracellular deposits of amyloid-β peptide (Aβ) and a severe depletion of the cholinergic system, although the relationship between these two events is poorly understood. In the neocortex, there is a loss of cholinergic fibers and receptors and a decrease of both choline acetyltransferase (ChAT) and acetylcholinesterase enzyme activities. The nucleus basalis of Meynert (NBM), which provides the major cholinergic input to the neocortex, undergoes profound neuron loss in AD. In the present study, we have examined the cholinergic alterations in amyloid precursor protein transgenic mice (APP23), a mouse model of cerebral β-amyloidosis. In aged APP23 mice, our results reveal modest decreases in cortical cholinergic enzyme activity compared with age-matched wild-type mice. Total cholinergic fiber length was more severely affected, with 29 and 35% decreases in the neocortex of aged APP23 mice compared with age-matched wild-type mice and young transgenic mice, respectively. However, there was no loss of cholinergic basal forebrain neurons in these aged APP23 mice, suggesting that the cortical cholinergic deficit in APP23 mice is locally induced by the deposition of amyloid and is not caused by a loss of cholinergic basal forebrain neurons. To study the impact of cholinergic basal forebrain degeneration on cortical amyloid deposition, we performed unilateral NBM lesions in adult APP23 mice. Three to 8 months after lesioning, a 38% reduction in ChAT activity and significant cholinergic fiber loss were observed in the ipsilateral frontal cortex. There was a 19% decrease in Aβ levels of the ipsilateral compared with contralateral frontal cortex with no change in the ratio of Aβ40 to Aβ42. We conclude that the severe cholinergic deficit in AD is caused by both the loss of cholinergic basal forebrain neurons and locally by cerebral amyloidosis in the neocortex. Moreover, our results suggest that disruption of the basal cholinergic forebrain system does not promote cerebral amyloidosis in APP23 transgenic mice.

[1]  P. Kelly,et al.  Progressive age-related impairment of cognitive behavior in APP23 transgenic mice , 2003, Neurobiology of Aging.

[2]  M. Staufenbiel,et al.  Amyloid-Associated Neuron Loss and Gliogenesis in the Neocortex of Amyloid Precursor Protein Transgenic Mice , 2002, The Journal of Neuroscience.

[3]  C. Haass,et al.  Protofibrils, the unifying toxic molecule of neurodegenerative disorders? , 2001, Nature Neuroscience.

[4]  E. Mufson,et al.  Neuropathology of Mice Carrying Mutant APPswe and/or PS1M146L Transgenes: Alterations in the p75NTR Cholinergic Basal Forebrain Septohippocampal Pathway , 2001, Experimental Neurology.

[5]  E. McGowan,et al.  Survival and plasticity of basal forebrain cholinergic systems in mice transgenic for presenilin-1 and amyloid precursor protein mutant genes , 2001, Neuroreport.

[6]  M. Staufenbiel,et al.  Comparative Analysis of Amyloid-β Chemical Structure and Amyloid Plaque Morphology of Transgenic Mouse and Alzheimer's Disease Brains* , 2001, The Journal of Biological Chemistry.

[7]  M. Staufenbiel,et al.  Spontaneous Hemorrhagic Stroke in a Mouse Model of Cerebral Amyloid Angiopathy , 2001, The Journal of Neuroscience.

[8]  D. Moechars,et al.  Acetylcholinesterase-Positive Fiber Deafferentation and Cell Shrinkage in the Septohippocampal Pathway of Aged Amyloid Precursor Protein London Mutant Transgenic Mice , 2000, Neurobiology of Disease.

[9]  J. Trojanowski,et al.  Brain Trauma in Aged Transgenic Mice Induces Regression of Established Aβ Deposits , 2000, Experimental Neurology.

[10]  I. Tesseur,et al.  Prominent cerebral amyloid angiopathy in transgenic mice overexpressing the London mutant of human APP in neurons , 2000, Neurobiology of Aging.

[11]  T. Beach,et al.  The Cholinergic Deficit Coincides with Aβ Deposition at the Earliest Histopathologic Stages of Alzheimer Disease , 2000, Journal of neuropathology and experimental neurology.

[12]  T. Beach,et al.  Cholinergic deafferentation of the rabbit cortex: a new animal model of Aβ deposition , 2000, Neuroscience Letters.

[13]  B. Sommer,et al.  Neuronal overexpression of mutant amyloid precursor protein results in prominent deposition of cerebrovascular amyloid. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[14]  O. Isacson,et al.  Cognitive changes and modified processing of amyloid precursor protein in the cortical and hippocampal system after cholinergic synapse loss and muscarinic receptor activation. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[15]  M. Frotscher,et al.  Cerebral Amyloid Induces Aberrant Axonal Sprouting and Ectopic Terminal Formation in Amyloid Precursor Protein Transgenic Mice , 1999, The Journal of Neuroscience.

[16]  D. Selkoe,et al.  Translating cell biology into therapeutic advances in Alzheimer's disease , 1999, Nature.

[17]  B. Sommer,et al.  Association of microglia with amyloid plaques in brains of APP23 transgenic mice. , 1999, The American journal of pathology.

[18]  Sarah Tomlin,et al.  Microtechnology: Laying it on thick , 1999, Nature.

[19]  K. Duff,et al.  Reorganization of Cholinergic Terminals in the Cerebral Cortex and Hippocampus in Transgenic Mice Carrying Mutated Presenilin-1 and Amyloid Precursor Protein Transgenes , 1999, The Journal of Neuroscience.

[20]  D. Ingram,et al.  Hippocampal neuron and synaptophysin-positive bouton number in aging C57BL/6 mice , 1998, Neurobiology of Aging.

[21]  B. Sommer,et al.  Neuron loss in APP transgenic mice , 1998, Nature.

[22]  John M. Lee,et al.  Pharmacological Drug Treatment of Alzheimer Disease: The Cholinergic Hypothesis Revisited , 1998, Journal of neuropathology and experimental neurology.

[23]  G. Halliday,et al.  Neurofibrillary degeneration and cell loss in the nucleus basalis in comparison to cortical Alzheimer pathology , 1998, Neurobiology of Aging.

[24]  R. Polinsky,et al.  Dose‐dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease , 1998, Acta neurologica Scandinavica.

[25]  C. Geula,et al.  Relationship Between Plaques, Tangles, and Loss of Cortical Cholinergic Fibers in Alzheimer Disease , 1998, Journal of neuropathology and experimental neurology.

[26]  R. Quirion,et al.  β-Amyloid peptides as direct cholinergic neuromodulators: a missing link? , 1998, Trends in Neurosciences.

[27]  B. Sommer,et al.  Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[28]  U. Ueberham,et al.  In Vivo Regulation of Amyloid Precursor Protein Secretion in Rat Neocortex by Cholinergic Activity , 1997, European Journal of Neuroscience.

[29]  L. Harrell,et al.  Cholinergic activity and amyloid precursor protein metabolism , 1997, Brain Research Reviews.

[30]  John Hardy,et al.  Amyloid, the presenilins and Alzheimer's disease , 1997, Trends in Neurosciences.

[31]  R. Powers,et al.  Cholinergic activation of phosphoinositide signaling is impaired in Alzheimer's disease brain , 1997, Neurobiology of Aging.

[32]  D. Selkoe,et al.  Alzheimer's Disease--Genotypes, Phenotype, and Treatments , 1997, Science.

[33]  M. Schachner,et al.  Expression of the neural adhesion molecule L1 in the deafferented dentate gyrus , 1996, Neuroscience.

[34]  S. Younkin,et al.  Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice , 1996, Science.

[35]  L. Mucke,et al.  Comparison of Neurodegenerative Pathology in Transgenic Mice Overexpressing V717F β-Amyloid Precursor Protein and Alzheimer’s Disease , 1996, The Journal of Neuroscience.

[36]  J. Blusztajn,et al.  Amyloid beta-protein reduces acetylcholine synthesis in a cell line derived from cholinergic neurons of the basal forebrain. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[37]  M. Staufenbiel,et al.  Electrophoretic Separation of βA4 Peptides (1–40) and (1–42) , 1996 .

[38]  P. Paganetti,et al.  Effect of alkalizing agents on the processing of the β-amyloid precursor protein , 1996, Brain Research.

[39]  Claudia Linker,et al.  Acetylcholinesterase Accelerates Assembly of Amyloid-β-Peptides into Alzheimer's Fibrils: Possible Role of the Peripheral Site of the Enzyme , 1996, Neuron.

[40]  B. Sommer,et al.  Expression of APP in transgenic mice: a Comparison of neuron-specific promoters , 1996, Neurobiology of Aging.

[41]  F. Gage,et al.  Essential role of neocortical acetylcholine in spatial memory , 1995, Nature.

[42]  L. Mucke,et al.  Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein , 1995, Nature.

[43]  K. Davis,et al.  Neurochemical Correlates of Dementia Severity in Alzheimer's Disease: Relative Importance of the Cholinergic Deficits , 1995, Journal of neurochemistry.

[44]  E. Pioro,et al.  Neocortical infarction in subhuman primates leads to restricted morphological damage of the cholinergic neurons in the nucleus basalis of Meynert , 1994, Brain Research.

[45]  J. Coyle,et al.  Cholinergic innervation of mouse forebrain structures , 1994, The Journal of comparative neurology.

[46]  J. Growdon,et al.  Activation of protein kinase C inhibits cellular production of the amyloid beta-protein. , 1993, The Journal of biological chemistry.

[47]  M. Goedert.  Tau protein and the neurofibrillary pathology of Alzheimer's disease , 1993, Trends in Neurosciences.

[48]  W. Benzing,et al.  Immunocytochemical distribution of peptidergic and cholinergic fibers in the human amygdala: their depletion in Alzheimer's disease and morphologic alteration in non-demented elderly with numerous senile plaques , 1993, Brain Research.

[49]  Mark J. West,et al.  New stereological methods for counting neurons , 1993, Neurobiology of Aging.

[50]  E. B. VEDEL JENSEN,et al.  The rotator , 1993 .

[51]  D. Selkoe,et al.  Mutation of the β-amyloid precursor protein in familial Alzheimer's disease increases β-protein production , 1992, Nature.

[52]  P. Greengard,et al.  Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer beta/A4 amyloid protein precursor. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[53]  A. Shetter,et al.  Cortical biopsy in Alzheimer's disease: Diagnostic accuracy and neurochemical, neuropathological, and cognitive correlations , 1992 .

[54]  J. Growdon,et al.  Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. , 1992, Science.

[55]  E. Perry,et al.  Convergent cholinergic activities in aging and Alzheimer's disease , 1992, Neurobiology of Aging.

[56]  C. Geula,et al.  Cholinesterases in the amyloid angiopathy of Alzheimer's disease , 1992, Annals of neurology.

[57]  E. Hirsch,et al.  Alzheimer's disease: Is the decrease of the cholinergic innervation of the hippocampus related to intrinsic hippocampal pathology? , 1992, Neuroscience.

[58]  C V Howard,et al.  Estimating neuron dendritic length in 3D from total vertical projections and from vertical slices , 1992, Acta neurologica Scandinavica. Supplementum.

[59]  E. Mufson,et al.  Ultrastructural localization of acetylcholinesterase in neurofibrillary tangles, neuropil threads and senile plaques in aged and Alzheimer's brain , 1992, Brain Research.

[60]  H. Gundersen,et al.  Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator , 1991, The Anatomical record.

[61]  R. Gaykema,et al.  Cortical projection patterns of the medial septum‐diagonal band complex , 1990, The Journal of comparative neurology.

[62]  R. Nieuwenhuys,et al.  Cell loss and shrinkage in the nucleus basalis Meynert complex in Alzheimer's disease , 1990, Neurobiology of Aging.

[63]  J. Moossy,et al.  A brain regional analysis of morphologic and cholinergic abnormalities in Alzheimer's disease. , 1989, Archives of neurology.

[64]  Gwenn S. Smith.  Animal models of Alzheimer's disease: experimental cholinergic denervation , 1988, Brain Research Reviews.

[65]  H. J. G. GUNDERSEN,et al.  Some new, simple and efficient stereological methods and their use in pathological research and diagnosis , 1988, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[66]  D. Collerton,et al.  Cholinergic function and intellectual decline in Alzheimer's disease , 1986, Neuroscience.

[67]  D. Price,et al.  A modified histochemical technique to visualize acetylcholinesterase-containing axons. , 1985, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[68]  J. Grassi,et al.  An Immunological Study of Rat Acetylcholinesterase: Comparison with Acetylcholinesterases from Other Vertebrates , 1984, Journal of neurochemistry.

[69]  L. Iversen,et al.  Correlation of cortical cholinergic and GABA deficits with quantitative neuropathological findings in senile dementia. , 1984, Brain : a journal of neurology.

[70]  T. Powell,et al.  Retrograde changes in cholinergic neurons in the basal forebrain of the rat following cortical damage , 1983, Brain Research.

[71]  J. Coyle,et al.  Topographic analysis of the innervation of the rat neocortex and hippocampus by the basal forebrain cholinergic system , 1983, The Journal of comparative neurology.

[72]  D L Price,et al.  Alzheimer's disease: a disorder of cortical cholinergic innervation. , 1983, Science.

[73]  M. Esiri,et al.  Alzheimer's disease Correlation of cortical choline acetyltransferase activity with the severity of dementia and histological abnormalities , 1982, Journal of the Neurological Sciences.

[74]  R. Bartus,et al.  The cholinergic hypothesis of geriatric memory dysfunction. , 1982, Science.

[75]  J. Coyle,et al.  Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. , 1982, Science.

[76]  E. Perry,et al.  Neurochemical activities in human temporal lobe related to aging and Alzheimer-type changes , 1981, Neurobiology of Aging.

[77]  K. E. Moore,et al.  Decrease of neocortical choline acetyltransferase after lesion of the globus pallidus in the rat , 1978, Experimental Neurology.

[78]  F. Fonnum,et al.  A rapid radiochemical method for the determination of choline acetyltransferase , 1975, Journal of neurochemistry.

[79]  K. Courtney,et al.  A new and rapid colorimetric determination of acetylcholinesterase activity. , 1961, Biochemical pharmacology.

[80]  E. Mufson,et al.  Colocalization of cholinesterases with β amyloid protein in aged and Alzheimer's brains , 2004, Acta Neuropathologica.

[81]  B. Sommer,et al.  Pathogenesis and Mechanism of Cerebral Amyloidosis in APP Transgenic Mice , 2001 .

[82]  H. Braak,et al.  Evolution of Alzheimer’s disease-related cytoskeletal changes in the basal nucleus of Meynert , 2000, Acta Neuropathologica.

[83]  B. Hyman,et al.  Microglial response to amyloid plaques in APPsw transgenic mice. , 1998, The American journal of pathology.

[84]  D. Selkoe.  Alzheimer's disease: genotypes, phenotypes, and treatments. , 1997, Science.

[85]  J. Kornhuber,et al.  Improved electrophoretic separation and immunoblotting of beta‐amyloid (Aβ) peptides 1–40, 1–42, and 1–43 , 1997, Electrophoresis.

[86]  J. McArthur,et al.  An unbiased method for estimation of total epidermal nerve fibre length , 1996, Journal of neurocytology.

[87]  M. Staufenbiel,et al.  Electrophoretic separation of betaA4 peptides (1-40) and (1-42). , 1996, Analytical biochemistry.

[88]  M M Mesulam,et al.  The systems-level organization of cholinergic innervation in the human cerebral cortex and its alterations in Alzheimer's disease. , 1996, Progress in brain research.

[89]  P. Paganetti,et al.  Effect of alkalizing agents on the processing of the beta-amyloid precursor protein. , 1996, Brain research.

[90]  D. Selkoe,et al.  Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. , 1992, Nature.